JP6896628B2 - 細菌感染症の治療のための抗微生物性ポリミキシン - Google Patents

細菌感染症の治療のための抗微生物性ポリミキシン Download PDF

Info

Publication number
JP6896628B2
JP6896628B2 JP2017532053A JP2017532053A JP6896628B2 JP 6896628 B2 JP6896628 B2 JP 6896628B2 JP 2017532053 A JP2017532053 A JP 2017532053A JP 2017532053 A JP2017532053 A JP 2017532053A JP 6896628 B2 JP6896628 B2 JP 6896628B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
compound
atoms
biaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017532053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502845A (ja
JP2018502845A5 (cg-RX-API-DMAC7.html
Inventor
フェドロビッチ ゴルデエフ ミハイル
フェドロビッチ ゴルデエフ ミハイル
リウ ジンキアン
リウ ジンキアン
ワング ジングハイ
ワング ジングハイ
ユアン ズヘンギュ
ユアン ズヘンギュ
Original Assignee
シャンハイ ミクウルク ファーマシューティカル シーオー.エルティーディー
シャンハイ ミクウルク ファーマシューティカル シーオー.エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ ミクウルク ファーマシューティカル シーオー.エルティーディー, シャンハイ ミクウルク ファーマシューティカル シーオー.エルティーディー filed Critical シャンハイ ミクウルク ファーマシューティカル シーオー.エルティーディー
Publication of JP2018502845A publication Critical patent/JP2018502845A/ja
Publication of JP2018502845A5 publication Critical patent/JP2018502845A5/ja
Application granted granted Critical
Publication of JP6896628B2 publication Critical patent/JP6896628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2017532053A 2014-12-16 2015-12-16 細菌感染症の治療のための抗微生物性ポリミキシン Active JP6896628B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092780P 2014-12-16 2014-12-16
US62/092,780 2014-12-16
PCT/US2015/066210 WO2016100578A2 (en) 2014-12-16 2015-12-16 Antimicrobial polymyxins for treatment of bacterial infections

Publications (3)

Publication Number Publication Date
JP2018502845A JP2018502845A (ja) 2018-02-01
JP2018502845A5 JP2018502845A5 (cg-RX-API-DMAC7.html) 2019-02-28
JP6896628B2 true JP6896628B2 (ja) 2021-06-30

Family

ID=55456866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532053A Active JP6896628B2 (ja) 2014-12-16 2015-12-16 細菌感染症の治療のための抗微生物性ポリミキシン

Country Status (8)

Country Link
US (1) US9771394B2 (cg-RX-API-DMAC7.html)
EP (1) EP3233889B1 (cg-RX-API-DMAC7.html)
JP (1) JP6896628B2 (cg-RX-API-DMAC7.html)
KR (1) KR102585108B1 (cg-RX-API-DMAC7.html)
CN (1) CN107257803B (cg-RX-API-DMAC7.html)
CA (1) CA2970546A1 (cg-RX-API-DMAC7.html)
ES (1) ES2924058T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016100578A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189866A1 (en) * 2016-04-27 2017-11-02 Spero Opco Polymyxin analogs useful as antibiotic potentiators
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
WO2019084628A1 (en) 2017-11-02 2019-05-09 The University Of Queensland Peptide antibiotics
CA3102833A1 (en) * 2018-06-12 2019-12-19 University Of Manitoba Preparation of dilipid polymyxins and use thereof as antimicrobial adjuvants
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
GB201904534D0 (en) * 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof
US12435108B2 (en) 2019-07-24 2025-10-07 Sunshine Lake Pharma Co., Ltd. Teixobactin analogue and use thereof
CN111072757B (zh) * 2020-01-02 2021-10-15 上海上药第一生化药业有限公司 多黏菌素b组分或其盐及其制备方法和应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
WO2023001224A1 (en) * 2021-07-21 2023-01-26 Shanghai Micurx Pharmaceutical Co., Ltd. Novel compounds and compositions for targeted therapy of renal cancers
WO2023001223A1 (en) * 2021-07-21 2023-01-26 Shanghai Micurx Pharmaceutical Co., Ltd. Compounds and compositions for targeted therapy of renal diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450687A (en) 1966-02-24 1969-06-17 Pfizer & Co C Lower alkanoyl esters of polymyxin antibiotics
DE1906699A1 (de) 1968-02-12 1970-02-05 Pfizer Neue Polymyxinderivate und Verfahren zu deren Herstellung
US4091092A (en) 1976-09-20 1978-05-23 E. R. Squibb & Sons, Inc. Polymyxin F and process of producing polymyxin F
JPS5831918B2 (ja) 1976-10-27 1983-07-09 塩野義製薬株式会社 新規抗生物質ポリミキシンs↓1
US6380356B1 (en) 1999-12-07 2002-04-30 Advanced Medicine, Inc. Multivalent polymyxin antibiotics
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
WO2006045156A1 (en) 2004-10-29 2006-05-04 Monash University Therapy for multi-drug resistant microorganisms
KR100750658B1 (ko) 2005-12-09 2007-08-20 한국생명공학연구원 폴리믹신 생합성 효소 및 이를 코딩하는 유전자 군
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US9096649B2 (en) 2008-02-08 2015-08-04 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
NZ598074A (en) 2009-09-01 2014-04-30 Fab Pharma Sas Novel antibacterial hydroxyphenyl compound
JP5353680B2 (ja) 2009-12-18 2013-11-27 船井電機株式会社 光ディスク装置
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
MX355217B (es) 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
CN103130876B (zh) 2011-11-30 2014-07-23 广东双柏药业有限公司 一种高纯度多粘菌素b的制备方法
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
EP2884989A4 (en) 2012-08-17 2016-03-23 Univ Houston System LIPOSOMAL FORMULATIONS OF POLYMIXIN AND USES THEREOF
EP2909220B1 (en) 2012-10-18 2016-11-23 Dow Global Technologies LLC Phosphorous-containing aluminum carboxylate salt flame retardants
CN103044529B (zh) * 2012-12-06 2018-01-30 山东鲁抗医药股份有限公司 一种在硫酸多粘菌素b中提取b1单组份的方法
CA2895910C (en) 2013-01-11 2021-12-21 Xellia Pharmaceuticals Aps Polymyxins, compositions, methods of making and methods of use
CN103923190B (zh) 2013-01-14 2018-04-03 上海医药工业研究院 从多黏菌素b的混合组分中分离纯化多黏菌素b1的方法
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
WO2015031602A1 (en) 2013-08-29 2015-03-05 Rhk Technology, Inc. Optical alignment interface
KR20160135739A (ko) * 2014-03-11 2016-11-28 뉴 파마 라이센스 홀딩스 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds

Also Published As

Publication number Publication date
US9771394B2 (en) 2017-09-26
JP2018502845A (ja) 2018-02-01
ES2924058T3 (es) 2022-10-04
EP3233889B1 (en) 2022-07-06
KR102585108B1 (ko) 2023-10-05
KR20170086671A (ko) 2017-07-26
CN107257803A (zh) 2017-10-17
EP3233889A2 (en) 2017-10-25
CA2970546A1 (en) 2016-06-23
CN107257803B (zh) 2021-02-05
US20160185823A1 (en) 2016-06-30
WO2016100578A2 (en) 2016-06-23
WO2016100578A3 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
KR102585108B1 (ko) 세균 감염의 치료를 위한 항미생물성 폴리믹신
CN109422752B (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
JP7184646B2 (ja) ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法
CN109516989B (zh) 一类抑制并降解cdk的化合物
JP2020536082A (ja) 細菌感染症を治療するためのクロマンモノバクタム化合物
JP2018502845A5 (cg-RX-API-DMAC7.html)
TW201431866A (zh) 硼酸衍生物及其治療用途
JP6130600B2 (ja) トリサイクリックベンズオキサボロール化合物、その製造方法および用途
JP2015502974A (ja) 抗微生物療法のための三環式ホウ素化合物
WO2023125928A1 (zh) Menin抑制剂及其用途
JP5152527B2 (ja) ペネムプロドラッグ
KR20120089437A (ko) 플라빈 유도체
CN108137574A (zh) 羟烷基噻二唑衍生物
CN104066738A (zh) 新型抗菌化合物
JPWO2011013735A1 (ja) 新規フラバノン誘導体
CN115974855A (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
WO2019232083A1 (en) Compounds and methods for treating bacterial infections
WO2024123929A1 (en) Development of potent dual hdac/brd4 inhibitors
CN119630393A (zh) 抗微生物化合物
CA3239097A1 (en) Prodrugs of boron compounds and their use in treating bacterial infections
FR2995605A1 (fr) Derives de macrolides, leur preparation et leur application therapeutique.
WO2022253316A1 (zh) 一类喹喔啉衍生物及其制备和用途
JP2004137185A (ja) チオフェン骨格を有する抗菌剤
JP2017105714A (ja) 多剤排出ポンプ阻害剤
RU2782469C2 (ru) Апоптоз-индуцирующие агенты

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210609

R150 Certificate of patent or registration of utility model

Ref document number: 6896628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250